Who are The Pfizer mRNA-based BNT162b2 vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Combination BNT162b2 and BNT162b2 OMI, Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose, BNT162b7 Bivalent (Original/OMI BA.4/BA.5), Comirnaty Omicron XBB.1.5, Pfizer-COVID-19 Vaccine, mRNA-1283.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/the-pfizer-mrna-based-bnt162b2-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

The Pfizer mRNA-based BNT162b2 vaccine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Pfizer mRNA-based BNT162b2 vaccine (The Pfizer mRNA-based BNT162b2 vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: mRNA vaccine. Area: Immunology / Infectious Disease.

marketed mRNA vaccine SARS-CoV-2 spike protein (S protein) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

The Pfizer mRNA-based BNT162b2 vaccine (The Pfizer mRNA-based BNT162b2 vaccine) — dafna yahav. BNT162b2 is an mRNA vaccine that instructs cells to produce the SARS-CoV-2 spike protein, triggering an immune response to prevent COVID-19 infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
The Pfizer mRNA-based BNT162b2 vaccine TARGET	The Pfizer mRNA-based BNT162b2 vaccine	dafna yahav	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
Combination BNT162b2 and BNT162b2 OMI	combination-bnt162b2-and-bnt162b2-omi	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein
Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose	variant-adapted-bnt162b2-omicron-xbb-1-5-10-microgram-dose	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein
BNT162b7 Bivalent (Original/OMI BA.4/BA.5)	bnt162b7-bivalent-original-omi-ba-4-ba-5	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein
Comirnaty Omicron XBB.1.5	Comirnaty Omicron XBB.1.5	Jules Bordet Institute	marketed	mRNA vaccine	SARS-CoV-2 spike protein (XBB.1.5 variant)
Pfizer-COVID-19 Vaccine	Pfizer-COVID-19 Vaccine	National Heart, Lung, and Blood Institute (NHLBI)	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
mRNA-1283	mRNA-1283	ModernaTX, Inc.	marketed	mRNA vaccine	HPV16 and HPV18 antigens (E6 and E7 proteins)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (mRNA vaccine class)

Pfizer · 12 drugs in this class
ModernaTX, Inc. · 11 drugs in this class
BioNTech SE · 5 drugs in this class
Jules Bordet Institute · 5 drugs in this class
Tan Tock Seng Hospital · 2 drugs in this class
Clover Biopharmaceuticals AUS Pty · 1 drug in this class
CanSino Biologics Inc. · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
CSPC Megalith Biopharmaceutical Co.,Ltd. · 1 drug in this class
Jens D Lundgren, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). The Pfizer mRNA-based BNT162b2 vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/the-pfizer-mrna-based-bnt162b2-vaccine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab